In its base case, Investec expects a strong FY26, followed by moderation in FY27, with EPS growth resuming in FY28. In the ...

Investec also raises its price target on Lupin to Rs 2,265 from Rs 2,100, implying an upside of around 14 per cent from ...

Global brokerage Investec upgraded Lupin to a ‘buy’ from the previous ‘hold’ and also lifted its price target by 8% to ₹2,265 ...

Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced ...

Indias top drugmakers, Sun Pharmaceutical Industries (NSE:SUN) and Lupin Ltd (NSE:LUPN), are moving closer to developing affordable anti-obesity drugs as the country faces a growing health crisis.

USFDA inspections at Lupin, Zydus, and Aurobindo facilities result in observations, commitment to compliance with quality ...

Sun Pharma and Lupin pursue regulatory approval for oral weight-loss drugs, potentially reshaping treatment access.

Mumbai: Lupin has received two observations from the U.S. Food and Drug Administration (USFDA) at the closure of an ...

Catalyst Pharmaceuticals ( NASDAQ: CPRX) said that the company and licensor SERB S.A. signed a settlement agreement with Lupin Pharmaceuticals, putting an end to a patent lawsuit.

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) is among the fastest growing small cap stocks to buy. Lupin Inc., a leading player in ...

Pursuant to the terms of the Agreement, Lupin will not market its generic version of FIRDAPSE in the United States any earlier than February 25, 2035, if approved by the U.S. Food and Drug ...